Roche doubles down on Poseida
A $1bn buyout gives Roche more allogeneic Car-T projects, plus non-viral gene therapy contenders.
Jefferies 2024 – Cargo tries again with an old idea
A CD22-directed Car that has had several owners will next year deliver its most important dataset.
ASH 2024 preview – Arcellx disappoints
An ASH abstract reveals no delayed neurotoxicity, but three deaths, with anito-cel.
The month ahead: November’s upcoming events
Conferences ramp up, and ASH abstracts near.
Clouds loom for Novartis’s MorphoSys buy
Pelabresib is delayed, and Novartis writes off $800m of the €2.7bn purchase.
Carvykti takes off
Meanwhile, Tecvayli stalls, but J&J still hopes for growth.
